A new FDA-approved drug brings in a lot of hope for men with aggressive prostate cancer, as it may increase their chances of survival by 40 per cent. According to experts, the combination of two drugs
- enzalutamide and leuprolide - significantly improves overall survival rates. This advance could actually change the way doctors approach treatment for this fast-growing cancer, offering patients a better chance at longer, healthier lives. Dr Stephen Freedland, a professor of urology at Cedars-Sinai Medical Center in Los Angeles, part of the trial, said that it would mean that a 70-year-old man whose prostate cancer recurs could live about another 15 years. "For many of these patients, I think we are turning [prostate cancer] into a chronic disease, which is really exciting,” he said. Across the world, prostate cancer is the second leading cause of cancer death among men, behind lung cancer. Studies say about one in three men treated with surgery or radiation for prostate cancer have what doctors call a "biochemical recurrence," meaning their PSA levels double in just nine months or less, but imaging cannot detect a tumour. The combination treatment for the trials included enzalutamide, which is marketed under the brand name Xtandi, and leuprolide, a hormone therapy that lowers testosterone. Among those who took the drug combination, 79 per cent of the participants of the study were still alive after eight years, compared to 73 per cent for enzalutamide alone and 70 per cent for leuprolide alone. Doctors say that, till now, no other treatment for recurrence has come close to these results.
Are there any side effects of this drug combo?
According to experts, there are significant side effects of this, which include:- Fatigue
- Enlarged breasts – also known as gynecomastia
- Lower libido
/images/ppid_a911dc6a-image-17627624283921914.webp)



/images/ppid_a911dc6a-image-176248815203837944.webp)


/images/ppid_59c68470-image-176253754830958752.webp)

/images/ppid_a911dc6a-image-176254402733285632.webp)
/images/ppid_a911dc6a-image-176249362600232420.webp)
/images/ppid_a911dc6a-image-176249082625999306.webp)